Topas Therapeutics

Topas Therapeutics Focuses on Developing Products to Address Key Unmet Needs, Including Autoimmune Diseases, Allergies, and Anti-Drug Antibodies. Topas' technology platform induces antigen-specific immune tolerance by leveraging the liver's natural immune functions, targeting liver sinusoidal endothelial cells (LSECs) to generate tolerance to blood-borne antigens. Topas particle conjugates mimic such blood-borne antigens and follow their natural processing pathway in LSECs, including the generation of long-lasting antigen-specific regulatory T cells (Tregs), which are crucial immune cell types for maintaining immune tolerance. Topas' innovative technology enables the development of new therapeutic approaches for challenging diseases.